在雄性大鼠的阿片类药物诱导性便秘中,电 ?? 的自主效应
Misaki Okada1,2, Kazunori Itoh1, Hiroshi Kitakoji2
1Department of Acupuncture and Moxibustion, Meiji University of Integrative Medicine, Kyoto, Japan.
Physiological reports
|October 14, 2025
概括
电针 (EA) 通过影响自主神经系统,有效改善大鼠的阿片类药物诱导性便秘 (OIC). 这项研究澄清了EA.
科学领域:
- 胃肠病学 胃肠病学
- 神经科学是一个神经科学.
- 综合医学是一个整体的医学.
背景情况:
- 阿片类药物诱导的便秘 (OIC) 是阿片类药物治疗的常见副作用.
- 需要进一步阐明OIC的潜在机制和电针 (EA) 的疗效.
- 之前的报道表明EA的OIC潜力,但缺乏详细的机制研究.
研究的目的:
- 在OIC的老鼠模型中研究EA影响自主神经系统的机制.
- 评估EA在ST-36针点对洛佩拉米德诱导的延迟结肠过渡 (CT) 的治疗效果.
- 阐明自主神经系统在调解EA对OIC的影响中的作用.
主要方法:
- 通过使用局部μ-阿片类受体激动剂洛佩拉米德建立了OIC的老鼠模型.
- 在诱导OIC后,使用放射性色标记物和X射线成像测量了结肠过渡 (CT).
- 电针 (EA) 在ST-36针点应用,其效果与药理干预措施 (氨酸,α-腺受体对抗剂,乙胆酶抑制剂) 结合评估.
主要成果:
- 洛佩拉米德在老鼠中显著延迟了结肠过渡 (CT),建立了一个有效的OIC模型.
- 在ST-36的EA治疗显著改善了洛佩拉胺诱导的CT延迟.
- EA对CT延迟的有益作用被阿特罗平取消,这表明胆固醇系统的参与.
- 通过α-腺受体对抗剂和乙胆酶抑制剂加速CT延迟,进一步影响自主神经系统.
结论:
- 在大鼠模型中,电针 (EA) 在改善阿片类药物诱导的便秘 (OIC) 中表现出显著的疗效.
- 在OIC中EA的有效性机制涉及自主神经系统的调节,特别是胆固醇通路.
- 这些发现支持EA作为管理OIC的潜在治疗策略,突出了自主神经系统在其作用中的重要性.
更多相关视频
03:50Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease
Published on: August 18, 2023
2.7K
04:33Effects of Different Connection Modes of Electroacupuncture on Electrocardiogram and Nerve Discharge in Rats
Published on: January 3, 2025
610
相关概念视频
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
617
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
617
Drugs for Treatment of Diarrhea-Predominant IBS
631
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
631
Drugs for Treatment of Constipation-Predominant IBS
717
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
717
